Version July 2025
Dental aid: Pass the impregnated cord around the neck of the tooth and place into gingival sulcus; leave cord in sulcus for up to 5 minutes; normal tissue moisture, water, or gingival retraction solutions activate impregnated cord. Limit use to one quadrant of the mouth at a time.
There are no dosage adjustments provided in the manufacturer’s labeling.
There are no dosage adjustments provided in the manufacturer’s labeling.
Refer to adult dosing; use with caution.
No data reported.
Hypersensitivity to epinephrine, sulfites, aluminum-containing products, or any component of the formulation; cardiovascular disease, hypertension, hyperthyroidism, diabetes, or congestive glaucoma; concurrent antidepressant use; do not apply to areas of heavy or deep bleeding or overexposed bone
Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.
Other warnings/precautions:
• Appropriate use: Caution should be exercised whenever using gingival retraction cords with epinephrine since it delivers vasoconstrictor doses of racemic epinephrine to patients; the general medical history should be thoroughly evaluated before using in any patient.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Retraction cord, for gingival sulcus placement:
GingiBRAID +:
0e fine: Epinephrine 0.10 – 0.30 mg and aluminum potassium sulfate 0.05 – 0.25 mg per inch
1e small: Epinephrine 0.20 – 0.60 mg and aluminum potassium sulfate 0.15 – 0.35 mg per inch
2e medium: Epinephrine 0.40 – 0.80 mg and aluminum potassium sulfate 0.20 – 0.50 mg per inch
3e large: Epinephrine 0.60 – 1.20 mg and aluminum potassium sulfate 0.30 – 0.80 mg per inch
No
Dental aid: Aids in temporary gingival retraction and hemostasis procedures
Refer to individual components.
Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program by clicking on the “Launch drug interactions program” link above.
Monoamine Oxidase Inhibitors (Antidepressant): May increase adverse/toxic effects of Epinephrine (Racemic). Risk X: Avoid
Selective Serotonin Reuptake Inhibitor: May increase adverse/toxic effects of Epinephrine (Racemic). Risk X: Avoid
Serotonin Reuptake Inhibitor/Antagonists: May increase adverse/toxic effects of Epinephrine (Racemic). Risk X: Avoid
Serotonin/Norepinephrine Reuptake Inhibitor: May increase adverse/toxic effects of Epinephrine (Racemic). Risk X: Avoid
Tricyclic Antidepressants: May increase adverse/toxic effects of Epinephrine (Racemic). Risk X: Avoid
Epinephrine stimulates alpha1 adrenergic receptors to cause vasoconstriction in blood vessels in gingiva; aluminum potassium sulfate, precipitates tissue and blood proteins
No data reported.
